Use of specifically engineered enzymes to enhance the efficacy of prodrugs
US7419811B2 · kind B2 · utility
6Cited by
1References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 1, 2004 |
| Grant date | Sep 2, 2008 |
| Priority date | — |
| Expiry date | Mar 1, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.